thymopentin has been researched along with Skin Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 4 (57.14) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Han, Z; Li, J; Li, P; Wang, F; Xiao, Y; Zhang, Q; Zhang, X; Zheng, L | 1 |
| Braun-Falco, O; Burg, G; Przybilla, B; Schmoeckel, C | 1 |
| Baldini, M; Bufalino, R; Cascinelli, N; Clemente, C; Mascheroni, L; Mihm, MC; Zurrida, S | 1 |
| Foss, FM; Kuzel, TM | 1 |
| Baldini, MT; Belli, F; Bufalino, R; Cascinelli, N; Clemente, C; Mascheroni, L; Mihm, MC; Rao, S | 1 |
| Belli, F; Cascinelli, N; Clemente, C; Lenisa, L; Mascheroni, L | 1 |
| Agolzer, A; Trevisan, G | 1 |
1 review(s) available for thymopentin and Skin Neoplasms
| Article | Year |
|---|---|
Experimental therapies in the treatment of cutaneous T-cell lymphoma.
Topics: Antibodies, Monoclonal; Humans; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Purines; Recombinant Fusion Proteins; Retinoids; Skin Neoplasms; Thymopentin | 1995 |
4 trial(s) available for thymopentin and Skin Neoplasms
| Article | Year |
|---|---|
Treatment of cutaneous T-cell lymphomas with TP-5. Evaluation of the clinical effect in 8 patients.
Topics: Adult; Aged; Clinical Trials as Topic; Female; Hormones; Humans; Lymphoma; Male; Middle Aged; Mycosis Fungoides; Peptide Fragments; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes; Thymopentin; Thymopoietins; Thymus Hormones; Time Factors | 1983 |
Perinodular injection of thymopentin (TP5) in cutaneous and subcutaneous metastases of melanoma.
Topics: CD3 Complex; Double-Blind Method; Humans; Injections; Leukocyte Common Antigens; Lymphocyte Subsets; Melanoma; Sclerosis; Skin Neoplasms; Thymopentin | 1993 |
Biological activity and clinical efficacy of intravenous high-dose thymopentin in metastatic melanoma patients.
Topics: Adjuvants, Immunologic; Adult; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Injections, Intravenous; Male; Melanoma; Middle Aged; Pilot Projects; Skin Neoplasms; Thymopentin | 1996 |
Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients.
Topics: Adjuvants, Immunologic; Adult; Aged; Female; Humans; Immunophenotyping; Injections, Intravenous; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Rate; Thymopentin; Treatment Outcome | 1998 |
2 other study(ies) available for thymopentin and Skin Neoplasms
| Article | Year |
|---|---|
The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Atrophy; B7-2 Antigen; Cyclophosphamide; Drug Synergism; Histocompatibility Antigens Class I; Hydrocortisone; Immunologic Factors; Immunosuppressive Agents; Interferon-gamma; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Protein Binding; Skin Neoplasms; Surface Plasmon Resonance; Thymalfasin; Thymocytes; Thymopentin; Thymosin; Thymus Gland; Time Factors; Toll-Like Receptor 2; Tumor Burden | 2013 |
[Thymopentin in the treatment of cutaneous melanoma].
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunity, Cellular; Male; Melanoma; Middle Aged; Peptide Fragments; Skin Neoplasms; Thymopentin; Thymopoietins; Thymus Hormones | 1989 |